Compare · KRRO vs NVO
KRRO vs NVO
Side-by-side comparison of Korro Bio Inc. (KRRO) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KRRO and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 1266.7x KRRO ($137.1M).
- Over the past year, KRRO is down 79.4% and NVO is down 28.6% - NVO leads by 50.8 points.
- NVO has been more active in the news (4 items in the past 4 weeks vs 3 for KRRO).
- Both have 25 recent analyst ratings on file.
- Company
- Korro Bio Inc.
- Novo Nordisk A/S
- Price
- $8.70-6.85%
- $38.82-1.05%
- Market cap
- $137.1M
- $173.66B
- 1M return
- -26.18%
- -10.14%
- 1Y return
- -79.36%
- -28.57%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- News (4w)
- 3
- 4
- Recent ratings
- 25
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest KRRO
- Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form 8-K filed by Korro Bio Inc.
- Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121
- Director Formela Jean Francois sold $686,177 worth of shares (48,690 units at $14.09) as part of a pre-agreed trading plan (SEC Form 4)
- Senior Vice President, Finance Dolan Oliver sold $69 worth of shares (5 units at $13.72) as part of a pre-agreed trading plan, decreasing direct ownership by 0.03% to 16,241 units (SEC Form 4)
- Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Senior Vice President, Finance Dolan Oliver sold $99,368 worth of shares (7,353 units at $13.51) as part of a pre-agreed trading plan, decreasing direct ownership by 31% to 16,246 units (SEC Form 4)
- Director Formela Jean Francois sold $4,188 worth of shares (300 units at $13.96) as part of a pre-agreed trading plan (SEC Form 4)
- Korro to Participate in Upcoming Investor Conferences
- Director Formela Jean Francois sold $398,552 worth of shares (28,468 units at $14.00) as part of a pre-agreed trading plan (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank